Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity

Anna Kruyer1,3, Jeffrey Parrilla-Carrero1,3, Courtney Powell1, Lasse Brandt2, Stefan Gutwinski2, Ariana Angelis1, Reda M. Chalhoub1, Thomas C. Jhou1, Peter W. Kalivas1 and Davide Amato1,2✉

© The Author(s) 2021

Antipsychotic-induced dopamine supersensitivity, or behavioral supersensitivity, is a problematic consequence of long-term antipsychotic treatment characterized by the emergence of motor abnormalities, refractory symptoms, and rebound psychosis. The underlying mechanisms are unclear and no approaches exist to prevent or reverse these unwanted effects of antipsychotic treatment. Here we demonstrate that behavioral supersensitivity stems from long-lasting pre, post and perisynaptic plasticity, including insertion of Ca2+-permeable AMPA receptors and loss of D2 receptor-dependent inhibitory postsynaptic currents (IPSCs) in D2 receptor-expressing medium spiny neurons (D2-MSNs) in the nucleus accumbens core (NAcore). The resulting hyperexcitability, prominent in a subpopulation of D2-MSNs (21%), caused locomotor sensitization to cocaine and was associated with behavioral endophenotypes of antipsychotic treatment resistance and substance use disorder, including disrupted extinction learning and augmented cue-induced cocaine-seeking behavior. Chemogenetic restoration of IPSCs in D2-MSNs in the NAcore was sufficient to prevent antipsychotic-induced supersensitivity, pointing to an entirely novel therapeutic direction for overcoming this condition.

Molecular Psychiatry (2021) 26:6159–6169; https://doi.org/10.1038/s41380-021-01235-6

INTRODUCTION
Antipsychotic drugs are widely prescribed to treat psychosis and many other psychiatric and non-psychiatric disorders [1–3]. Although they are an efficacious short-term intervention in most patients [4], chronic antipsychotic treatment is characterized by high relapse rates in patients with psychosis (70–80%) [5, 6]. Around 39% of these cases result from antipsychotic-induced dopamine supersensitivity [5], or simply behavioral supersensitivity, characterized by decreased therapeutic efficacy and emergence of motor side effects in compliant patients [7]. Although onset of behavioral supersensitivity often motivates patients to reduce or abstain from antipsychotic intake [6], discontinuation of antipsychotic treatment worsens symptoms of behavioral supersensitivity by further reducing efficacy of reinstated antipsychotic treatment (i.e., treatment resistance) [8–10], exacerbating the severity of motor side effects such as dyskinesias [7, 11] as well as psychotic symptoms [12, 13], and increasing the likelihood of future relapse [8, 13].

Antipsychotic-induced behavioral supersensitivity is hypothesized to result from enhanced sensitivity to dopamine via increased expression and/or sensitivity of the D2 receptor (D2r) in striatal neurons following long-term receptor blockade with antipsychotics [14, 15]. Despite many literary references to this hypothetical mechanism, some investigations show that the D2r is increased in roughly half of patients (5 out 9 patients, ~55.6%) after antipsychotic discontinuation (i.e., 14 days) and symptoms do not correlate with receptor upregulation [16]. Likewise, the D2r is not altered in most patients following longer periods of treatment discontinuation (4–6 months) [17–19] and relapse of symptoms appears to be temporally unrelated to putative D2r changes [8]. Furthermore, increased D2r expression or function is associated with high antipsychotic doses [20–22], whereas behavioral supersensitivity is associated with the duration of antipsychotic treatment in animal models [22–24]. Finally, behavioral supersensitivity can also occur during ongoing antipsychotic treatment [22, 24] when D2 receptors are significantly blocked [24]. Thus, while the underlying mechanisms are unclear, defining the cause of antipsychotic-induced supersensitivity remains a fundamentally important issue in psychiatry, since it is frequently observed and poses a severe burden on patients.

In this study, we examined the impact of chronic haloperidol treatment and discontinuation on D1- and D2-MSNs in the nucleus accumbens core (NAcore, the ventral extension of the caudate-putamen), a brain structure with high dopamine release capacity [25] involved in neuronal responses to antipsychotics [26] and in cocaine sensitization [27–29], and describe definitive mechanisms of antipsychotic-induced behavioral supersensitivity. Because the behavioral symptoms and neuroadaptations of antipsychotic-induced supersensitivity are more prominent after antipsychotic discontinuation [7–10], we focused on changes occurring during abstinence following chronic haloperidol treatment. We further identified specific behavioral symptoms associated with antipsychotic-induced supersensitivity in rodents, testing for psychomotor responses to cocaine, expression of...
vaccuous chewing movements (VCs), a surrogate measure of dyskinesia, and measures of both cocaine taking and seeking.

METHODS
Full methodological descriptions can be found in the Supplementary materials and methods.

Animals
We used male and female transgenic mice for all experiments except for operant behavior, where we used male and female wild-type Long Evans rats. All animals were bred in house and procedures involving the use of animals were conducted in accordance with guidelines established by the National Institutes of Health and approved by the Institutional Animal Care and Use Committee at the Medical University of South Carolina.

Locomotor sensitization and cross-sensitization
Mice undergoing cross-sensitization were implanted with subcutaneous osmotic infusion pumps (Alzet) delivering clinically relevant doses of haloperidol at 0.5 mg/kg/day for 14 days [24]. Mice were absten from haloperidol for an additional 7 days before undergoing locomotor cross-sensitization with cocaine (15 mg/kg, i.p.). Mice undergoing cocaine mono-sensitization received two cocaine injections (15 mg/kg, i.p.) separated by 7 days incubation as described in [30].

In vivo Ca²⁺ imaging
To study the activity of D1- and D2-MSNs in vivo we used D1- and D2-core mice as previously described [26, 31] to achieve selective expression of the Ca²⁺-sensing fluorophore GCaMP6f in D1- and D2-MSNs in the NAcore. Ca²⁺ traces from independent neurons were computed and Ca²⁺ events that were ≥6× the median absolute deviation of the input trace data and with a minimum mean decay of 0.1 s were included. Ca²⁺ events were transformed into binary values to obtain the absolute number of spikes per min over a period of 45 min. The absolute number of Ca²⁺ events that passed the sphericity test were categorized to determine distinct cell response patterns compared to baseline using unsupervised k-means clustering for parametric data. The optimal number of clusters was automatically selected using the fit statistic Cubic Cluster Criterion and subsequently categorized empirically as activated, inactivated, or unchanged.

Western blotting
Brains were extracted from mice and dorsal striatum, ventral striatum, midbrain, and cerebellum tissue extracts were dissected and manually homogenized in ice-cold RIPA buffer with protease and phosphatase inhibitors (Thermo Fisher). Protein content was determined using BCA (Thermo Fisher) and Western blotting was conducted using standard methodology. Blots were imaged using a Li-COR imaging system and the band corresponding to the D2r was identified based on its molecular weight (~50 kDa) and its absence in cerebellum extracts. Images were converted to grayscale and quantified using Fiji.

Ex vivo electrophysiology
Selective recordings of D2-IPSCs in the NAcore were conducted following overexpression of the GABA protein-coupled inwardly rectifying potassium channel (GIRK2) with a tdTomato-reporter in D2-MSNs. Pre and postsynaptic excitatory recordings were made from Drd1a-tdTomato and Drd2a-eGFP expressing MSNs in the NAcore.

Confocal microscopy
Mice received NAcore injections of AAV5.GFAP.HM3d.mCherry. After extraction, brains were sliced at 100 µm and sections were immunolabeled by incubation in primary and secondary antibodies. Immunolabeled tissue was imaged using an SP8 confocal microscope (Leica) and Z-stacks were deconvolved (Autoquant) and analyzed for fluorescence intensity using Bitplane Imaris. Astroglia were digitally isolated and their co-registration with Synapsin I was normalized to the astroglial volume and to total Synapsin I signal per equivalent stack size to account for changes in astroglial volume and Synapsin I density. GLT-1 expression that co-localized with Synapsin I was normalized to the astroglial volume. In all cases, data were ultimately normalized to the mean value of the untreated group.

DREADD inhibition of D2-MSNs
Mice were implanted with bilateral cannulae (Plastics One) above the NAcore along with osmotic pumps for subcutaneous haloperidol infusion. AAV2.FLEX.HM4D.imCherry (Addgene) or sterile saline was delivered 1.4 mm beyond the tip of the guide canulae and virus incubation occurred during 14 days of haloperidol treatment and 7 days of abstinence. Clozapine N-oxide (CNO, 1 mM, 0.3 µL, Abcam) was infused intracranially 5 min prior to cocaine injection (15 mg/kg, i.p.) and behavioral testing.

Cocaine self-administration
Rats were implanted with subcutaneous pumps delivering haloperidol (0.5 mg/kg/d, Alzet) for 14 days. On day 14, pumps were removed and animals were fitted with intrajugular catheters. Seven days after recovery from surgery, haloperidol pretreated rats and untreated controls began daily 2 h cocaine self-administration sessions, where active lever presses were paired with light and tone cues for 5 s and cocaine delivery (0.4 mg/kg/infusion). Inactive lever presses had no consequence. After 10 days of self-administration, rats underwent extinction training (2 h/d), where cues and cocaine delivery were withheld during active lever pressing. Extinction training continued for 12 days. The following day, rats were returned to the operant chamber and light/tone cue pairings were restored to the active lever during a 60-min session, but no cocaine was delivered.

Other behavioral testing
Methodological details are provided in the Supplementary materials and methods.

Statistics
Transformation of Ca²⁺ events into binary values was conducted using MATLAB and cluster analysis and relative data representations were performed using SAS statistics. Data were analyzed using a Student’s t test or one- or two-way ANOVA with repeated measures when possible. A Pearson’s correlation coefficient was calculated to determine the relationship between Ca²⁺ events and locomotion. In all cases, statistical significance was set at p < 0.05.

RESULTS
Neurobiology of antipsychotic-induced behavioral supersensitivity
Induction of behavioral supersensitivity. The symptoms of antipsychotic-induced behavioral supersensitivity can occur during ongoing antipsychotic treatment [22–24], but are exacerbated by treatment discontinuation [7–10], and are best modeled in rodents during locomotor sensitization to psychostimulants after chronic antipsychotic discontinuation [11, 22, 32]. For these reasons, we first tested whether discontinuation from chronic treatment with clinically equivalent doses of haloperidol heightened the psychomotor response to a single cocaine injection in mice. In keeping with clinically valid scenarios, animals underwent continuous haloperidol treatment via osmotic infusion (0.5 mg/kg/d) through the expression of treatment failure (i.e., acquired resistance, 14 days in rodents) [23, 24, 33], a time at which most patients decide to discontinue antipsychotic treatment [6]. Animals then received a single dose of cocaine (15 mg/kg, i.p.) 7 days after haloperidol discontinuation.

In separate animals, we induced cocaine sensitization using two repeated cocaine injections (15 mg/kg, i.p.) to compare the sensitized responses to cocaine in the two groups—those pre-exposed to the antipsychotic (cross-sensitization) and those that received only cocaine (mono-sensitization) (Fig. 1A, B). Acute cocaine in animals pretreated with haloperidol enhanced locomotion (Fig. 1C) in a similar manner as in haloperidol-naïve animals that received repeated cocaine injections [30], demonstrating behavioral supersensitivity at this timepoint.
Behavioral supersensitivity coincided with the loss of D2r-mediated IPSCs. The most commonly cited cause of antipsychotic-induced behavioral supersensitivity is upregulated D2r expression after discontinuation of long-term antipsychotic treatment [7]. To test whether the D2r was upregulated in our model of behavioral supersensitivity, we examined D2r levels in the ventral striatum, dorsal striatum, midbrain, and cerebellum by western blot after 14 days of continuous haloperidol treatment, after 7 days of treatment discontinuation, and in control conditions. We found no change in D2r expression in either antipsychotic-treated group, or in animals that received a single cocaine injection followed by 7 days abstinence, relative to untreated control animals (Fig. 2A–D).

D2r is a metabotropic receptor coupled to G\(_{i/o}\) intracellularly that, when stimulated by dopamine, reduces cAMP production and cell excitability via the opening of the rectifier potassium channel GIRK2. In absence of D2r expression changes, we tested for a compensatory increase in D2r sensitivity after antipsychotic treatment. To do this, we overexpressed GIRK2 in the NAcore of D2-cre mice and measured dopamine D2r-dependent IPSCs as a sensor of D2r activation [26, 34, 35]. Interestingly electrical stimulation of dopamine terminals did not evoke D2r-dependent IPSCs during antipsychotic treatment or after treatment discontinuation (Fig. 2E), indicating a loss of function of the D2r to trigger its constitutive intracellular G\(_i\) inhibitory signaling. These data suggest that neither D2r expression nor putative increased function of the receptor can account for the expression of antipsychotic-induced behavioral supersensitivity.

Enhanced excitatory transmission on D2-MSNs during antipsychotic discontinuation. MSN excitability relies heavily on potassium-dependent intrinsic mechanisms and convergent glutamatergic inputs [36], which are both regulated by the D2r [36, 37]. Given the reduced D2r function in antipsychotic pretreated animals (Fig. 2E), we hypothesized that D2-MSNs would display a more depolarized resting membrane potential (RMP) and an augmented glutamate transmission after antipsychotic treatment. Accordingly, the RMP of D2-MSNs was depolarized in animals discontinuing the antipsychotic compared with controls (Fig. 2F).

Excitatory neurotransmission is altered by antipsychotic drugs at therapeutic equivalent doses, in part through increased recycling and readily releasable synaptic vesicle pools [24, 38]. Importantly, the machinery involved in synaptic vesicle trafficking is fundamental for the expression of short-term plasticity, such as neurotransmitter release facilitation [39]. To assess changes in glutamate transmission and relative neuroplasticity, we first examined whether glutamate release probability was altered by haloperidol discontinuation by measuring spontaneous excitatory postsynaptic currents (sEPSCs) and the paired-pulse ratio (PPR) of evoked excitatory postsynaptic currents (eEPSCs) in the NAcore. PPR was reduced on D2-MSNs during ongoing haloperidol treatment and after its discontinuation (Fig. 2G) and both frequency and amplitude of sEPSCs were increased after discontinuation (Fig. 2H), confirming both pre and postsynaptic potentiation of excitatory transmission onto NAcore D2-MSNs. No such changes were observed in NAcore D1-MSNs after haloperidol discontinuation (Fig. S1).

The initial release probability (i.e., first pulse of a train) of presynaptic excitatory transmission is directly related to vesicle pool size [39–41], and is regulated by Synapsin I, a prominent protein kinase substrate [41, 42] associated with readily releasable vesicles and with recycled synaptic vesicles following synaptic activity [43]. To validate our ex vivo finding, we used confocal microscopy and found increased density of Synapsin I-positive puncta in the NAcore after haloperidol discontinuation (Fig. 3A, D), indicating presynaptic changes consistent with increased vesicle pool size and supporting elevated glutamate release capacity at the first pulse (Fig. 2H). The injection of a single dose of cocaine reduced Synapsin I levels within 15 min, supporting a relationship between increased Synapsin I expression and increased transmitter release capacity during behavioral supersensitivity.

The extracellular concentration of glutamate is regulated presynaptically by astrocytes via their synaptic proximity and expression of the glutamate transporter GLT-1 that regulates glutamate uptake following synaptic release [44]. Both synaptic proximity of astroglial processes and surface diffusion of GLT-1 are dynamic and impact autoinhibitory control of excitatory transmission and postsynaptic excitation [45–49]. We measured changes in synaptic proximity of NAcore astroglia by quantifying confocal co-registration of mCherry-labeled astrocytes and immunoreactive Synapsin I. Synaptic co-registration of the astroglial membrane was reduced after chronic haloperidol treatment and discontinuation (Fig. 3E) consistent with synaptic retraction of astrocyte processes during behavioral supersensitivity. Synaptic insulation by astroglial processes permits efficient glutamate uptake through presynaptic proximity of GLT-1 [44]. Moreover, basal glutamate is regulated by astroglia that maintain tone on presynaptic autoreceptors via cystine-glutamate exchange [47]. Thus, retraction of astroglial processes is expected to disinhibit glutamate release, permit glutamate spillover and facilitate synaptic recruitment [46, 50]. We also found that GLT-1 expression increased during haloperidol treatment, but returned to baseline after treatment discontinuation, despite persistent increases in Synapsin I (Fig. 3F). The reduced synaptic proximity of astroglial
processes that harbor GLT-1 paired with its relative down-regulation after haloperidol discontinuation would be expected to increase and/or prolong excitatory transmission during behavioral supersensitivity.

Increased glutamatergic transmission leads to postsynaptic plasticity, commonly measured as an increase in current across α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAr) on dendritic spines, and relatively stable expression of N-methyl-D-aspartate receptors (NMDAr), resulting in changes in the ratio of synaptic currents through AMPAr and NMDAr [51–53]. Pharmacological isolation of AMPAr and NMDAr currents revealed an increased AMPA/NMDA receptor ratio in D2-MSNs (Fig. 4A), but not D1-MSNs during haloperidol discontinuation (Fig. 5B). This change was due to both a decrease in NMDAr-independent currents in D2-MSNs (Fig. 4B, C) and an increase in currents through Ca2+-permeable AMPAr (Fig. 4D), receptors that regulate several forms of synaptic plasticity [54].

We next evaluated the AMPAr component of evoked EPSCs in NACore D2-MSNs from mice pre-exposed to haloperidol and found that EPSCs at negative potentials were larger than those measured at positive potentials after antipsychotic treatment (Fig. 4D, insets). The I–V relationship shown in Fig. 4D confirms the rectification of EPSCs after pre-exposure to antipsychotic, but not in control conditions, and confirms insertion of Ca2+-permeable AMPAr during behavioral supersensitivity. Of note, since we obtained rectification of AMPAr currents using the weak channel blocker spermine (100 μM), we did not find it necessary to replicate the same result using a more potent channel blocker such as NASPAM [55]. We then applied high-frequency stimulation (HFS) of glutamatergic afferent fibers in the NACore to trigger long-term potentiation (LTP) and found that HFS induced LTP in control tissue as expected, but not in tissue from antipsychotic-treated mice (Fig. 4E), suggesting occlusion of LTP.

**D2-MSN hyperactivity during behavioral supersensitivity.** Based on our findings of enhanced D2-MSN excitability ex vivo, we next sought to determine whether NACore D2-MSN activity could be linked to behavioral supersensitivity in vivo. Spontaneous and sensitized locomotion and goal-directed behaviors are orchestrated by activity of D1- and D2-MSNs in the NACore [27–29, 56, 57]. To examine the cellular basis of locomotion during the expression of antipsychotic-induced behavioral supersensitivity, we recorded single-cell Ca2+ dynamics in 1852 MSNs in the NACore in vivo (Fig. S2, Table S1) during locomotor responses to cocaine in cross-sensitized (892 cells, Fig. S3B) and mono-sensitized (960 cells, Fig. S3A) mice. Unsupervised k-means
clustering revealed the underlying response structure of D1- and D2-MSNs in sensitized mice (Fig. S3C–F). Clusters with similar patterns over the recording session were combined and classified as unchanged, showing stable activity before and after i.p. cocaine, inactivated, showing depression of Ca2+ events in response to cocaine, or activated, showing increased Ca2+ activity after cocaine injection (Fig. 5A, B).

While MSNs were unchanged or inactivated in mono-sensitized mice (Fig. 5A), we found a subgroup of both D1- (66%) and D2- (21%) MSNs that were activated by a single dose of cocaine in cross-sensitized mice (Fig. 5B). Notably, the baseline activity of D2-MSNs was selectively enhanced relative to control conditions during ongoing chronic haloperidol treatment and after its discontinuation (Fig. 5D), consistent with our detection of enhanced excitatory plasticity in these cells. This increase in baseline activity was not observed in mono-sensitized animals and no change in baseline activity of D1-MSNs was observed in either mono- or cross-sensitized mice (Fig. 5C, D). When cell clusters were examined separately regarding their relationship to locomotor output, we found that unchanged and decreased MSNs in mono-sensitized and cross-sensitized mice either did not correlate or correlated negatively with locomotion (Fig. 5A, B, right panel). Instead, both D1- and D2-MSNs that were activated by cocaine in cross-sensitized mice correlated positively with locomotion (Fig. 5B, right panel), suggesting a role for hyperactive MSN subpopulations in mediating behavioral supersensitivity.

Interestingly, baseline activity of MSN subclusters after haloperidol discontinuation served as a reliable predictor of cellular responses to cocaine during cross-sensitization, in that higher baseline activity predicted depression of cellular response to cocaine and lower basal D2-MSN activity predicted cocaine-induced hyperactivity (Fig. 5A, B, right panel).

Restoration of G i intracellular signaling reversed behavioral supersensitivity. To assess the functional role of D2-MSN hyperactivation in the expression of behavioral supersensitivity, we virally delivered a G i-coupled designer receptor activated by the designer drug (DREADD) CNO [58] to D2-MSNs in the NAc, core of haloperidol pretreated mice (Fig. S5). Gi-DREADD expression would be expected to restore Gi-dependent IPSCs in D2-MSNs after haloperidol discontinuation. Mice that received CNO intracranially to inhibit D2-MSN activity did not exhibit locomotor cross-sensitization after cocaine injection compared with mice not expressing the Gi-DREADD (Fig. 5E). Thus, silencing hyperactive D2-MSNs suppressed locomotor cross-sensitization during behavioral supersensitivity. Locomotion in mice undergoing DREADD inhibition in D2-MSNs was comparable to locomotion in untreated mice that received acute haloperidol to suppress cocaine-induced locomotion (Fig. 5E), further confirming that suppression of NAc D2-MSN activity is necessary for antipsychotic efficacy as observed in acute administration paradigms [26].
Behavioral symptoms of antipsychotic-induced behavioral supersensitization

Antipsychotic-treatment resistance after discontinuation. Discontinuation of chronic antipsychotic treatment is a risk factor for diminished antipsychotic efficacy when treatment is reinstated (i.e., antipsychotic treatment resistance) [7–10]. We assessed the efficacy of an acute injection of haloperidol (0.5 mg/kg, i.p.) to inhibit hyperlocomotion induced by a single cocaine injection (15 mg/kg, i.p.) in mice naive to the antipsychotic and in mice that discontinued antipsychotic treatment (as in Fig. 1C). We found that while haloperidol effectively blocked the locomotor response to cocaine in animals naive to antipsychotic treatment, its efficacy was very much decreased in mice that had undergone antipsychotic discontinuation (Fig. 5E), consistent with treatment resistance after antipsychotic discontinuation.

VCMs were not observed in mice or rats after antipsychotic discontinuation. The occurrence of neurological symptoms such as dyskinesias are commonly thought to be associated with antipsychotic-induced behavioral supersensitization [7, 11]. We assessed if discontinuation from regimens of haloperidol treatment leading to behavioral supersensitivity also caused VCMs, a proxy for oral dyskinesias in mice and rats [59]. While mice displayed no visible dyskinesia at any point, symptoms were present in rats during ongoing treatment, but not after treatment discontinuation (Fig. 5E). To compare our own observations with different treatment protocols, we performed a systematic review of the literature on spontaneous VCMs in rodents. We searched PubMed, EMBASE, and Web of Science for relevant studies using search terms for animal studies, antipsychotics, and withdrawal. Of the literature on spontaneous VCMs in rodents. We searched PubMed, EMBASE, and Web of Science for relevant studies using search terms for animal studies, antipsychotics, and withdrawal.

Drug-seeking as an emergent consequence of antipsychotic discontinuation. The likelihood of substance use disorder in patients with schizophrenia is ~4.6-fold higher than in the general population [60, 61], especially among treatment non-adherent patients [62]. Interestingly, a small sample of non-psychotic drug-addicted patients was reported to co-abuse antipsychotic medications to enhance the effects of addictive substances [63]. This raises the question of whether discontinuing antipsychotic treatment enhances vulnerability to substance use disorder. Traditional animal models of drug addiction vulnerability involve locomotor sensitization induced by intermittent psychostimulant injections [64–67]. Because haloperidol and cocaine produced locomotor cross-sensitization, we sought to determine whether this response was predictive of additional behavioral features of substance use disorder using the self-administration, extinction, and reinstatement model of cocaine use and relapse.

We trained male and female rats to self-administer cocaine after abstinence from haloperidol according to the same timeline applied during locomotor cross-sensitization (Fig. 6A). Operant training was conducted on an FR1 schedule, and cocaine delivery was paired with light and tone cues for 2 h each day (Fig. 6B, Self-administration). There were no differences in active or inactive lever pressing between haloperidol pretreated and control animals during 10 days of self-administration (Figs. 6C, 5A), suggesting that the acquisition of learned operant responding for cocaine and total cocaine intake were not altered by haloperidol discontinuation. Next, active lever pressing was extinguished by removal of cocaine delivery and cues (Fig. 6B, Extinction). In control animals, active lever presses gradually decreased over time in the absence of drug reward and a stable baseline of responding was observed within 3–5 days of extinction training. In haloperidol-pretreated rats, however, active lever pressing was elevated compared to controls throughout extinction training and baseline responding in the drug-paired context remained elevated despite the absence of the reward (Fig. 5F, 6C). After 12 days of extinction, animals were returned to the operant box and light/tone pairings were restored to the active lever, but no cocaine was delivered (Fig. 6B, Reinstatement). Cocaine-associated cues stimulated lever pressing in haloperidol-pretreated rats compared to control animals during a 60-min reinstatement test (Figs. 6D, 6F, S9C, D), a widely accepted model of cue reactivity [68] linked to drug relapse in human patients [69]. Thus the main deficit emerging in supersensitive animals was surprisingly not an increase in cocaine intake as reported in studies applying mono-sensitization procedures [64], but involved disrupted extinction of operant responding (i.e., lever pressing) for cocaine despite its absence. Similarly, haloperidol pretreated animals displayed enhanced measures of seeking in response to drug-associated...
Fig. 5  Hyperactive D2-MSNs drive behavioral supersensitivity. Unsupervised k-means clustering was used to identify clusters of cells that were unchanged, inactivated, or activated by acute cocaine delivery (time 0) in animals undergoing mono- (A) or cross-sensitization (B). Ca²⁺ events in D1- or D2-MSNs over time shown as individual cells (left panel) or group means (middle panel; Mono-sens: Unchanged, two-way ANOVA Time F(4.477,492.5) = 12.98 p < 0.0001, p = 0.2712 0 vs. 5 min using Dunnet’s test; Inactivated, two-way ANOVA Time F(3.430, 754.6) = 55.74 p < 0.0001; Cross-sens: Unchanged, two-way ANOVA Time F(4.987,493.8) = 2.056 p = 0.0698; Inactivated, two-way ANOVA Time F(3.216, 308.7) = 35.15 p < 0.0001; Activated, two-way ANOVA Time F(4.074, 427.7) = 34.65 p < 0.0001). Right panel shows relationship between D1- and D2-MSN activity and locomotion averaged across animals in each time bin. C No difference was observed in D1- or D2-MSN activity during the baseline recording period before saline injection or the first or second cocaine injection in mono-sensitized mice (two-way ANOVA Treatment F(2,953) = 1.279 p = 0.2789). D Baseline D1-MSN activity was unchanged by continuous haloperidol treatment (Hal 14d) or haloperidol discontinuation (X-sens). Instead, D2-MSN activity was elevated during continuous haloperidol treatment and during treatment discontinuation (2-way ANOVA Treatment F(2,475) = 4.088 p = 0.0174, p < 0.05, ***p < 0.001 vs. Sal using Fisher’s test). E Stimulation of an inhibitory Gi-DREADD in NACore D2-MSNs prevented locomotor cross-sensitization (green) compared to animals not expressing the DREADD (yellow, two-way ANOVA Time × Treatment F(24,88) = 7.220 p < 0.0001, ****p < 0.0001 vs. Cross-sens: CNO). Notably, during cross-sensitization, acute haloperidol (red) was insufficient to blunt cocaine-induced hyperlocomotion compared with untreated animals (blue), ****p < 0.0001 vs. Cross-sens: Hal (acute). In A–E, N = 5 mice/grp (D2-MSNs) or 3–5 mice/grp (D1-MSNs).
cues, perhaps owing to a deficit in within-session extinction of behavioral responding in the absence of cocaine (Fig. S9C). Together, these data indicate that antipsychotic discontinuation may produce features of substance use disorder coincident with behavioral supersensitivity and point to antipsychotic discontinuation as a potential underlying factor contributing to the epidemiological observation that substance use disorder is often comorbid with schizophrenia and other psychiatric disorders where patients are medicated with antipsychotic drugs.

DISCUSSION

Summary of results
In the present study, we describe the neurobiology underlying antipsychotic-induced behavioral supersensitivity and provide new support for the active role of D2-MSNs in generating motor outputs in response to psychostimulants. Hyperexcitation of NAcore D2-MSNs was the main neuropathology emerging during chronic antipsychotic treatment (14 days, 0.5 mg/kg/d), treatment discontinuation (14 days treatment + 7 days withdrawal), and the expression of behavioral supersensitivity (14 days treatment + 7 days withdrawal + a single cocaine injection, 15 mg/kg i.p.). In ex vivo studies we determined that chronic treatment and discontinuation of clinically relevant doses of haloperidol were characterized by increased glutamatergic transmission onto D2-MSNs, but not D1-MSNs, accompanied by retraction of perisynaptic astrocytic processes and an increase in abundance of non-dopaminergic vesicles presynaptically without a corresponding increase in GLT-1 expression. We also confirmed D2-MSN hyperexcitation using in vivo Ca$^{2+}$ imaging during and after haloperidol treatment, and during antipsychotic-induced behavioral supersensitivity triggered by acute cocaine. D1-MSNs appeared to have preserved responses to cocaine, although their firing was not enhanced by haloperidol during or after treatment.

In separate animals, we found no increases in D2r density within regions of interest during or after haloperidol treatment and instead we found decreased ability of the D2r to elicit G$_i$-dependent IPSCs. When D2r function was restored via activation of Gi-DREADDs in freely moving animals, the expression of antipsychotic-induced behavioral supersensitivity was abolished. Animals with behavioral supersensitivity exhibited antipsychotic treatment resistance, since reinstated haloperidol treatment did not abolish the supersensitive response to cocaine in animals that had undergone chronic haloperidol pretreatment. We also observed tardive dyskinesia during, but not after chronic antipsychotic treatment. Most importantly, we found that antipsychotic discontinuation is a risk factor for substance use disorder since it impaired extinction of cocaine seeking, and enhanced cue-induced cocaine seeking during withdrawal in a rat model of addiction and relapse.

Neurobiology of behavioral supersensitivity
Very little is understood regarding the mechanisms by which chronic antipsychotic treatment or its discontinuation cause behavioral supersensitivity. The most common interpretation attributes this side effect to a potentiated D2r response to dopamine following receptor upregulation, and/or to greater expression of the high-affinity D2r isoform [14, 15], both of which have proven to be inconsistent in preclinical and clinical studies. While D2r density can be upregulated with high doses of D2 antagonists in animals according to some studies [20–22], antipsychotic-induced behavioral...
supersensitivitry is more consistently driven by the duration of treatment [22–24] and can occur without increases in receptor expression [16], including during ongoing treatment [22–24] while D2rs are substantially blocked [24].

We extend these previous observations by showing no upregulation of the D2r in the ventral striatum, dorsal striatum, or midbrain during chronic haloperidol treatment or after its discontinuation. Interestingly, there was a trend toward decreased expression of the receptor in the ventral striatum during behavioral supersensitivity. To measure potential changes in the sensitivity of the D2r to dopamine, we overexpressed the GIRK2 channel, which opens to hyperpolarize the neuronal membrane when dopamine stimulates the D2r [26, 34, 35]. Against our expectations, dopamine release, evoked by electrical stimulation of dopamine terminals, was unable to generate D2r-dependent Gi-mediated IPSCs in D2-MSNs over-expressing GIRK2. These data suggest that behavioral supersensitivity induced by antipsychotics is not related to increased D2r expression or function. Instead, when D2r function was effectively restored in D2-MSNs by activation of G\textsubscript{i}-DREADDs in freely moving animals, this intervention prevented the expression of antipsychotic-induced behavioral supersensitivity.

Taken together, our data indicate that the neurobiological pathway to antipsychotic-induced supersensitivity specifically involves enhanced excitability of D2-MSNs in the ventral striatum. NACore MSNs are less excitable than cortical neurons and their excitability is strongly regulated by glutamate neurotransmission. Accordingly, we show multiple measures of enhanced excitatory transmission converging selectively onto D2-MSNs in the NACore and involving pre-, post-, and perisynaptic adaptations. The imaging studies performed in vivo confirm this profound excitatory plasticity impacting NACore D2-MSNs as a pathology underlying antipsychotic-induced behavioral supersensitivity. Clusters of D2-MSNs were hyperactivated during chronic haloperidol treatment, after its discontinuation, and also in response to a single cocaine injection. Indeed, after haloperidol discontinuation, cocaine excited 21% of D2-MSNs, a response predicted by lower basal D2-MSN activity. While we do not address the mechanisms involved in triggering this glutamatergic dysregulation, based on our previous work [23, 24, 70, 71], we predict that hyperexcitability of D2-MSNs following antipsychotic treatment likely results from a lack of modulatory dopaminergic input, which is reduced after chronic antipsychotic treatment [23, 24]. rendering D2-MSNs hyperexcitable through incoming excitatory transmission. We obtained confirmation of the causality of D2-MSN hyperexcitability in behavioral supersensitivity since chemogenetic restoration of G\textsubscript{i} signaling in D2-MSNs was sufficient to prevent the supersensitive response to cocaine. Thus, we show that behavioral supersensitivity is characterized by an enduring sensitivity of D2-MSNs to glutamate, exacerbated by an insensitivity to dopamine, contrary to the oft-cited D2r-mediated mechanism.

A role for NACore D2-MSNs in motivated behavior

These data invite us to rethink the canonical role played by accumbens D2-MSNs in motor outputs. It is commonly thought that stimulation of D1 and D2 receptors with either dopamine or with direct and indirect agonists produce stimulation and inhibition of MSNs via the activation of intracellular G\textsubscript{as} or G\textsubscript{ia} proteins, respectively. On the contrary, we not only show that NACore D1-MSNs were not activated by cocaine during mono-sensitization, but also that silencing D2-MSNs inhibited locomotor activity in mice discontinuing antipsychotic treatment during cross-sensitization, revealing a subpopulation of D2-MSNs that can be triggered to drive hyperlocomotion. Furthermore, it is important to note that when MSN activity during cross-sensitization was averaged, D1- and D2-MSNs were increased and decreased in response to cocaine, respectively, in line with canonical expectations of the impact of cocaine on MSN activity (Fig. S10), though this “canonical” outcome was not observed in the mono-sensitized group. Importantly, while some D2r expression is expected from cholinergic interneurons in the NACore [72], hyperactive D2r-expressing cells in our study must necessarily be MSNs since they are 21% of labeled cells and cholinergic neurons are ~1% of neurons in the NACore [73]. Moreover, cholinergic neurons were excluded from electrophysiological recordings based on their morphology [26, 73].

Previous observations by others have explored the contribution of ongoing antipsychotic treatment to drug or food consumption [74, 75], but ours is the first to show that antipsychotic discontinuation leads to increased drug seeking through disrupted extinction of operant responding in drug-associated contexts and after exposure to drug-associated cues. Importantly, this model has high face and construct validity for human drug addiction [76]. Indeed, deficits in behavioral extinction and increased reinstated cocaine seeking in rodents would be expected to translate to increased drug relapse rates and shorter abstinence periods in humans undergoing parallel pharmacological treatments. These side effects coincide with long-lasting excitatory plasticity on D2-MSNs, but not D1-MSNs in the NACore. Since D2-MSNs have been shown to mediate both aversion and reward [77], increased lever pressing during extinction and reinstatement may derive from the enduring motivation of subjects to either reduce aversion during antipsychotic discontinuation or to achieve reward. Accordingly, although not true for all antipsychotics [78], it has been reported that antipsychotic treatment can induce negative symptoms in patients with psychosis [79] and in healthier volunteers [80].

Relevance for antipsychotic treatment in human patients

The presented data are of fundamental clinical importance since they describe the neurobiology of antipsychotic-induced behavioral supersensitivity and provide a description of the associated behavioral symptoms. Notably, our data show that antipsychotic discontinuation predisposes to antipsychotic resistance when treatment is reinstated and provides a mechanism to interpret previous observations on glutamate alterations in treatment-resistance patients [81]. We also discovered that antipsychotic discontinuation is likely a risk factor for substance use disorder in the absence of schizophrenia. Since we used animals that exhibited no symptoms of psychosis, our data describe neural adaptations induced pharmacologically by antipsychotics and therefore are relevant for patients with and without psychosis. Accordingly, since antipsychotic drugs are widely prescribed off-label [1], we propose the neurobiology and behavioral symptoms described in this study may affect both populations equally, a hypothesis we are currently testing.

While the focus of this report is on the mechanisms underlying antipsychotic-induced behavioral supersensitivity after treatment discontinuation, it should be noted that all of the measures of neuroplasticity observed in animals discontinuing haloperidol were also observed in animals during ongoing treatment. Therefore the mechanisms described in this report may help to interpret not only behavioral supersensitivity occurring after antipsychotic discontinuation, but also during ongoing treatment. These data might also suggest that behavioral supersensitivity induced by antipsychotic treatment is a progressive disorder beginning during treatment and worsening over time, independent from discontinuation.

In conclusion, the presented data reveal specific neurobiological mechanisms driving behavioral supersensitivity, a first step in identifying methods to treat it. While our data warn against adverse effects associated with long-term antipsychotic treatment and discontinuation, they also point to potential strategies to overcome them. For instance, incorporation of deep brain or transcranial magnetic stimulation at low frequencies [82, 83, 84] could be tested as a strategy to reduce or prevent excitatory plasticity on D2-MSNs, which we have shown to be causal in this disorder.
REFERENCES

1. Mark TL. For what diagnoses are psychotropic medications being prescribed?: a nationally representative survey of physicians. CNS Drugs. 2010;24:319–26.

2. Amato D, Vernon AC, Papaleo F. Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability. Neurosci Biobehav Rev. 2018;85:146–59.

3. Amato D, Beasley CL, Hahn MK, Vernon AC. Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. Neurosci Biobehav Rev. 2017;76:317–35.

4. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:539–51.

5. Fallon P, Dursun S, Deakin B. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012;2:13–22.

6. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:209–23.

7. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med. 1998;42:211–82.

8. Tihonen J, Tanskanen A, Taipale H. 20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175:75–83.

9. Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015;227:278–82.

10. Takeuchi H, Sui C, Remington G, Fervaha G, Zipursky RB, Foussias G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first-episode psychosis. Schizophrenia and related disorders. 2014;9:1036–42.

11. Tarsy D, Baldessarini RJ. Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neurropsychopharmacology. 1974;13:927–40.

12. Ekblom B, Eriksdotter L, Lindstrom LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology. 1984;83:293–4.

13. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114:3–13.

14. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science. 1977;196:906–8.

15. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, et al. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:867–72.

16. Amato D, Natesan S, Kapur S, Muller CP. Haloperidol modulates noradrenergic responses to aseveral stimulation depending on treatment duration. Behav Brain Res. 2011;221:313–11.

17. Marcott PF, Mamaligas AA, Ford CP. Phasic dopamine release drives rapid activation of striatal D2-receptors. Neuron. 2014;84:164–76.

18. Marcott PF, Gong S, Donthamsetti P, Grinnell SG, Nelson MN, Newman AH, et al. Regional heterogeneity of D2-receptor signaling in the dorsal striatum and nucleus accumbens. Neuron. 2018;98:575–8. e574

19. Tatsuki S, Misaki M, Missale C, Spano PF, Valerio A. Potassium channels involved in the transduction mechanism of dopamine D2 receptors in rat lactotrophs. J Physiol. 1989;410:251–65.

20. Tittschk NX, Sabatinii BL. Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuro. 2012;76:33–50.

21. de Bartolomeis A, Iasevoli F. The Homer family and the signal transduction system involved in the transduction mechanism of dopamine D2 receptors in rat lactotrophs. J Physiol. 2003;455:223–31.

22. Castelletti L, Memo M, Missale C, Spano PF, Valerio A. Potassium channels involved in the transduction mechanism of dopamine D2 receptors in rat lactotrophs. J Physiol. 2018;410:251–65.

23. Amato D, Canneva F, Cumming P, Maschauer S, Groos D, Wroch JK, et al. A dopamineergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry. 2018;25:2101–18.

24. Jones SR, O’Dell SJ, Marshall JF, Wightman RM. Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse. 1996;23:224–31.

25. Aronson-Carrero J, Kruyer A, Chilhoub RM, Powell C, Resenber A, Amato D. Neuronal connectivity of a supersensitive antipsychotic response. Research Square. 2020. Preprint.

26. Sjögren T, Bell K, Dufy P, Kalivas PW. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J Neurosci. 1996;16:1550–60.

27. Cadoni C, Solinas M, Di Chiaro G. Psychostimulant sensitization: differential characteristics of shell vs. core dopamine. J Pharmacol. 2000;388:69–76.

28. Li Y, Acerbo MJ, Wightman RM. The induction of behavioural sensitization is associated with cocaine-induced structural plasticity in the core (but not shell) of the nucleus accumbens. Eur J Neurosci. 2004;20:1647–54.

29. Valjent E, Bertran-Gonzalez J, Aubier B, Greengard P, Herve D, Girault JA. Mechanisms of locomotor sensitization to drugs of abuse in a two-injection protocol. Neurropsychopharmacology. 2010;35:401–15.

30. Resendeza SL, Jennings HJ, Ung RL, Nambodiri VM, Zhou ZC, Ottis JM, et al. Visualization of cortical, subcortical and deep brain neural circuit dynamics during naturalistic mammalian behavior with head-mounted microscopes and chronically implanted lenses. Nat Protoc. 2016;11:566–97.

31. Fukushima DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:867–72.

32. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med. 1998;42:211–82.

33. Dobrunz LE, Stevens CF. Heterogeneity of release probability, facilitation, and depletion at central synapses. Neuron. 1997;18:995–1008.

34. Cesca F, Baldelli P, Valtorta F, Benfenati F. The synapins: key actors of synapse function and plasticity. Prog Neurobiol. 2010;91:313–48.

35. Lou X, Fan F, Messa M, Raimondi A, Wu Y, Looger LL, et al. Reduced release probability prevents vesicle depletion and transmission failure at dynamin mutant synapses. Proc Natl Acad Sci USA. 2012;109:5159–523.

36. Rossali TW, Spillane D, Misler M, Herz J, Selig DK, Wolff J, et al. Essential functions of synapins I and II in synaptic vesicle regulation. Nature. 1995;375:488–93.

37. Bloom O, Evergren E, Tomlin N, Kjærulf O, Low P, Brodin L, et al. Colocalization of synapin and actin during synaptic vesicle recycling. J Cell Biol. 2003;161:737–47.

38. Banenbo FC. Glutamate uptake. Prog Neurobiol. 2001;65:1–105.

39. Kruyer A, Scofield MD, Wood D, Reisner JK, Kalivas PW. Heroin cues-evoked astrocytic structural plasticity at nucleus accumbens synapses inhibits heroin seeking. Biol Psychiatry. 2019;86:811–9.

40. Lehre KP, Rusakov DA. Asymmetry of glia near central synapses favors pre-synaptically directed glutamate escape. Biophysical J. 2002;83:125–34.

41. Baker DA, Shen H, Kalivas PW. Cytochrome/ glutamate exchange serves as the source for extracellular glutamate: modifications by repeated cocaine administration. Amino Acids. 2002;23:161–2.

42. Murphy-Royal C, Dupuis JP, Varela JA, Panatier A, Pinson B, Baufreton J, et al. Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nat Neurosci. 2015;18:219–26.

43. Kruyer A, Kalivas PW. Heroin cues reveal astroglial heterogeneity in the nucleus accumbens core. 2020. https://www.bionxiv.org/content/10.1101/2020.07.22.216036v1.

44. Henneberger C, Bard L, Panatier A, Reynolds JP, Kopach O, Medvedev NI, et al. LTP induction boosts glutamate spillover by driving withdrawal of perisynaptic astroglia. Neuro. 2020;108:919–36. e911.
51. Isaac JT, Nicoll RA, Malenka RC. Evidence for silent synapses: implications for the expression of LTP. Neuron. 1995;15:427–34.
52. Liao D, Hessler NA, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature. 1995;375:400–4.
53. Takahashi T, Sivoboda K, Malinow R. Experience strengthening transmission by driving AMPA receptors into synapses. Science. 2003;299:1585–8.
54. Cull-Candy S, Kelly L, Farrant M. Regulation of Ca2+-permeable AMPA receptors: synaptic plasticity and beyond. Curr Opin Neurobiol. 2006;16:288–97.
55. Coombs ID, Bats C, Craig AS, Cull-Candy SG, Farrant M. Intracellular NASPM allows an unambiguous functional measure of GluA2-lacking calcium-permeable AMPA receptor prevalence. 2021. https://www.biorxiv.org/content/10.1016/j.tob.2021.02.18.
56. Kelley AE, Gauthier AM, Lang CG. Amphetamine microinjections into distinct striatal subregions cause dissociable effects on motor and ingestive behavior. Behav Brain Res. 1989;35:27–39.
57. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16:223–44.
58. Mahler SV, Vazey EM, Beckley JT, Keistler CR, McGlinchey EM, Kauffling J, et al. Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking. Nat Neurosci. 2014;17:577–85.
59. Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology. 1986;88:403–19.
60. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epide-
miologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–8.
61. Shaner A, Khalsa ME, Roberts L, Wilkins J, Anglin D, Wilkins J, et al. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry. 1993;150:758–62.
62. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.
63. Malekshahi T, Toledo N, Ahmed N, Campbell AN, Haller D. Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse. J Subst Abus Treat. 2015;48:8–12.
64. Horger BA, Shleton K, Schenk S. Preexposure sensitizes rats to the rewarding effects of cocaine. Pharmacol Biochem Behav. 1990;37:707–11.
65. Regier DA, Farmer ME, Rae DS, Locke BZ, Keight SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epide-
miologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–8.
66. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16:223–44.
67. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-
sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247–91.
68. de Wit H, Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology. 1981;75:134–43.
69. Carter BL, Tiffany ST. Meta-analysis of cue-reactivity in addiction research. Addiction. 1999;94:327–42.
70. Amato D, Kruyer A, Samaha AN, Heinz A. Hypofunctional dopamine uptake and transporters in schizophrenia. Biol Psychiatry. 2006;63:231–7.
71. Demjash A, Eerton A, Makriyannis A, Kapur S, Hongue OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11–13.
72. Koubissez MZ, Kahriman E, Syed T, Miller J, Durand DM. Low-frequency electrical stimulation of a fiber tract in temporal lobe epilepsy. Ann Neurol. 2013;74:223–31.
73. Schrader LM, Stern JM, Wilson CL, Fields TA, Salamon N, Nuver MR, et al. Low frequency electrical stimulation through subdural electrodes in a case of refractory status epilepticus. Clin Neurophysiol. 2006;117:781–88.
74. Fregni F, Otachi PT, Do Valle A, Boggio PS, Thut G, Rigonatti SP, et al. A random-
ized clinical trial of repetitive transcranial magnetic stimulation in patients with refractory epilepsy. Ann Neurol. 2006;60:447–55.

ACKNOWLEDGEMENTS
We thank Mr. Eric Dreschewitz and Drs. Shanna Resende, Qing Liu, Alexia Thomas, Rusty Nall, Jasper Heinsbroek, and Pete Vento for technical assistance. We thank Dr. Christopher Ford for donating the GIRQ virus.

AUTHOR CONTRIBUTIONS
DA conceived the study, DA and AK designed and performed the calcium imaging, and the behavioral experiments with the assistance of CP, AA, and RC. LB and SG performed the meta-analysis. JPC and DA designed and interpreted the electrophysiology studies and JPC performed and analyzed the electrophysiology experiments. DA, AK, and JPC analyzed the data. DA and AK drafted the manuscript and all authors edited the final version of the manuscript.

FUNDING
DA and the entire study were supported by Deutsche Forschungsgemeinschaft (AM 488/1-1, 1-2, 2-1) and the Brain & Behavior Research Foundation (NARSAD Young Investigator Award 2018). Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41380-021-01235-6.
Correspondence and requests for materials should be addressed to D.A.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021

Molecular Psychiatry (2021) 26:6159–6169

A. Kryuer et al.

6169

Molecular Psychiatry (2021) 26:6159–6169

A. Kryuer et al.

6169

Molecular Psychiatry (2021) 26:6159–6169

A. Kryuer et al.

6169